presented by martin schlumberger at 2014 asco annual meeting
Post on 24-Feb-2016
89 Views
Preview:
DESCRIPTION
TRANSCRIPT
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT)
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Disclosures
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Study Rationale
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Study 303: Study Schema
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Patient Characteristics
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Primary Endpoint:<br />Kaplan-Meier Estimate of PFS
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
PFS by Previous VEGF-Targeted Therapy
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
PFS Subgroup Analyses
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Response Rates
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Best Tumor Response
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Overall Survival, ITT population
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Study Medication Exposure
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Treatment-emergent Adverse Events (TEAEs)
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Most Frequent Treatment-related Adverse Events (> 20%)
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
TEAEs of Special Interest
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Conclusions
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Slide 17
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
top related